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Background: Surrogate markers of colorectal inﬂammation are
increasingly being recognized as important in diﬀerentiating or-
ganic from functional intestinal disorders. Fecal calprotectin (FC)
can be easily measured in the stool, being released by leukocytes in
inﬂammatory conditions.
Aim: We evaluated FC as an index of inﬂammation in consecutive
outpatients referred for colonoscopy for chronic, nonbloody diarrhea.
Methods: Stool specimens of 346 outpatients with chronic, non-
bloody diarrhea, referred for colonoscopy, were measured for FC
levels. The proportion of patients correctly diagnosed with the test
and the relationship with endoscopic and histologic ﬁndings were
measured.
Results: Abnormal endoscopic ﬁndings were detected in 104 pa-
tients (30.1%). Histologic ﬁndings included 142 patients (41.0%)
with inﬂammation and 204 (59.0%) without inﬂammation. Fecal
excretion of calprotectin signiﬁcantly correlated with the ﬁnding of
inﬂammation at endoscopy and histology (P<0.0001). When
150mcg/g of stool was used as the upper reference limit, FC
showed 75.4% sensitivity and 88.3% speciﬁcity, with 81.7%
positive and 83.7% negative predictive values for histologic
inﬂammation.
Conclusions: In outpatients referred for colonoscopy a measure-
ment of FC is accurate to identify those with histologic in-
ﬂammation. Assay of FC may be a reliable and noninvasive
screening tool to identify inﬂammatory causes of chronic, non-
bloody diarrhea.
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Despite expert-based diagnostic criteria, it is still diﬃcultin routine clinical practice to make a diﬀerential di-
agnosis between organic [ie, infections, inﬂammatory bowel
disease (IBD), or neoplasm] and functional intestinal
pathology [eg, irritable bowel syndrome (IBS)].1 In fact,
only about one third of all patients who present with
chronic diarrhea have a ﬁrm diagnosis based upon their
initial history and physical examination.2 Certain signs and
symptoms associated with chronic diarrhea, such as rectal
bleeding, fever, and leukocytosis, are suggestive of in-
ﬂammatory disorders and, in such cases, stool triage would
not be a necessary component of the diagnostic algorithm.
For the remaining majority of chronic diarrhea patients the
ensuing clinical evaluation can be prolonged, invasive, and
resource intensive.3
Simple screening tests may be useful for discriminating
the presence or absence of organic pathology, and could
help direct the diagnostic work-up in a timelier and cost-
eﬀective manner to avoid inherent risks associated with
diagnostic procedures.4 Routine blood tests that use bio-
markers of inﬂammation are neither speciﬁc nor sensitive
enough because they are indirect measures of inﬂammation.
The fecal occult-blood test has a low sensitivity for a di-
agnosis of colon cancer, especially at an early stage.5 In the
case of bowel disease, the level of inﬂammation biomarkers
in the stool would appear to be the ideal test for mucosal
involvement.6
In the past few years, several leukocyte-derived pro-
teins excreted in stools have been proposed as markers of
intestinal inﬂammation.7 Fecal calprotectin (FC) is a
36.5 kDa, nonglycosylated calcium and zinc binding pro-
tein with antimicrobic, immunomodulatory, and anti-
proliferative properties. It is present in mucous membrane
squamous epithelium, but not in the normal intestinal
mucosa, and accounts for about 60% of total (cytosol
soluble) proteins in neutrophils granulocytes.8 The mucosal
barrier is altered in intestinal inﬂammation, allowing white
cells to cross the intestinal wall. Neutrophil determination
in stool is ineﬃcient because its brief lifetime makes it
mandatory that the sample should be examined within a
few hours of its collection.9 FC is resistant to bacterial
proteolytic degradation during passage through the gas-
trointestinal tract, and shows high stability in feces (>7d)
at diﬀerent temperatures, and can be easily measured,10
making it a surrogate marker of neutrophils inﬂux into the
bowel lumen. As a result, it has been suggested that FC
could be considered a simple, noninvasive, and reliable
screening method for detecting intestinal inﬂammation.
Aim of our study was to assess the diagnostic per-
formance of FC as a stool-screening biomarker for organic
intestinal disease. Therefore, we assessed FC levels in con-
secutive adult outpatients with unexplained chronic, non-
bloody diarrhea referred for colonoscopy.
MATERIALS AND METHODS
Patients
We prospectively studied adult (age of at least 18 y)
consecutive patients referred to evaluate chronic (Z4wk),
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nonbloody diarrhea of unknown origin at our gastro-
enterology outpatient department (Gastroenterology and
Hepatology Unit, University of Palermo) between March
2004 and May 2009.
Exclusion criteria were overt gastrointestinal bleeding,
known colorectal or gastric neoplasia, familial ad-
enomatous polyposis and hereditary nonpolyposis colo-
rectal cancer syndrome, history of colonic surgery, recent
respiratory or urinary tract infection, acute infectious di-
sease, pregnancy and alcohol abuse (consumption>30 g/d
in men and>20 g/d in women), intake of nonsteroidal
anti-inﬂammatory drugs, aspirin, and anticoagulants within
the previous month. None of our patients have had a pre-
vious diagnosis of colorectal disease.
A full medical history, including current smoking
habits, and common use of medications, was obtained from
all patients enrolled in the study, and a physical examina-
tion was performed. In addition, venous blood samples
were taken from all patients for complete blood count and
biochemical analysis, including erythrocyte sedimentation
rate (ESR), C-reactive protein, serum electrolytes, thyroid
hormones, and liver and renal function tests. Stool cultures
and search for ova and parasites were done. All patients
underwent colonoscopy with biopsies. All patients gave the
informed consent for FC evaluation assay and supplied a
single stool sample before the bowel preparation for colo-
noscopy. Small bowel enteroclysis and upper gastro-
intestinal endoscopy with distal duodenal biopsies were
done in all patients in whom Crohn’s disease was histo-
logically diagnosed, to deﬁne the extension of the disease.
Gastroenterologists were unaware of the FC results
throughout the study.
Patients with negative results for all of the examina-
tions described above, and with a clinical history indicative
of nonorganic disease, were then considered to be suﬀering
from IBS, according to Rome II criteria.11 Organic diseases
were diagnosed using generally accepted conventional
criteria.
Demographic and clinical characteristics, biochemical
data, endoscopic, and histologic ﬁndings were recorded in
an electronic database.
Stool Collections
Stool specimens were collected and returned by each
study subject in a disposable plastic bucket-like device to
avoid toilet water artefacts and to simplify laboratory
sampling. Upon receipt, stool samples were aliquoted for
immediate assay or stored at 201C until assay.
FC Assay
Fecal assays were performed at a single laboratory by
experienced laboratory technicians, without prior know-
ledge of the clinical diagnoses or details of the patients’
clinical histories. Calprotectin concentrations were de-
termined using the commercially available enzyme-linked
immunosorbent assay test (Calprest, Eurospital SpA,
Trieste, Italy), a quantitative enzyme-linked immunoassay
that uses polyclonal antibodies against calprotectin. Ali-
quots of approximately 100mg feces (range, 40 to 120mg)
were homogenized for 25±5 minutes with extraction
buﬀer. After homogenate (1mL) centrifugation for 20 mi-
nutes at 10.000 rpm, the supernatant (0.5mL) was diluted
1:50. A 100mL sample was added in duplicate to each well,
which had been previously coated with antibody. Standards
contained calprotectin at known concentrations. After
45±5 minutes of incubation at room temperature, wash-
ing was followed by the addition of 100 mL of conjugate
and, after adding 100mL substrate and incubation at room
temperature for 30 minutes in a dark place, the optical
density values were read at 405 nm. Results were recorded
as a continuous variable (in mcg/g of stool) based on preset
threshold values supplied by the manufacturer (<250mcg/g
of stool=negative, Z250mcg/g of stool=positive).
Endoscopy
Colonoscopies were performed by experienced staﬀ
gastroenterologists who were unaware of the FC results.
Cecal intubation, coupled with >90% mucosal surface
visualization, constituted a complete examination. Mucosal
abnormalities were recorded by anatomic subsite and bi-
opsies were obtained from the terminal ileum, right colon,
left colon, and rectum. The following endoscopic diagnoses
were considered: normal endoscopic signs, ﬁndings of IBD,
diverticular disease with or without peridiverticular in-
ﬂammation, polyps, and ischemic colitis.
Histologic Examination
Histopathologic evaluations of colorectal inﬂamma-
tion were made by experienced gastrointestinal histo-
pathologists, who were blinded to the FC results. Histologic
inﬂammation was deﬁned by histologic standard criteria
and subtyped as: Crohn’s disease, ulcerative colitis, micro-
scopic colitis. Colitis was deﬁned as nonspeciﬁc when the
pathologist was not able to formulate a diagnosis for lack
of clinical data or insuﬃcient information. To correlate FC
levels and histologic ﬁndings, colorectal inﬂammation
was graded as 0 to 2 (0=normal mucosa, 1=mild in-
ﬂammation with mild/no, glandular distortion, and
2=severe inﬂammation, with glandular distortion).
Statistical Analysis
Continuous variables were summarized as median and
range, and categorical variables as frequency and percent-
age. Data were previously examined by a normality test. A
P value of <0.05 was considered statistically signiﬁcant.
To predict colorectal inﬂammation at histology, a
backward logistic regression was ﬁtted to the data. The
patients were grouped according to the histopathologic
ﬁndings; a dichotomous variable was assigned to each pa-
tient that was a value of 1 for patients with colorectal in-
ﬂammation and 0 for patients without. Multiple linear
regression analysis was done to identify independent pre-
dictors of FC levels as continuous dependent variables in all
groups of patients.
Box plots were used to provide an immediate graphical
evaluation of FC values by the endoscopic and histologic
ﬁndings. Correlation between the high level of FC and the
presence of lesions (endoscopic and histologic) was esti-
mated by the Spearman correlation rank coeﬃcient.
Parameters of FC reliability, including sensitivity,
speciﬁcity, positive and negative predictive values were
calculated by construction of a receiver operating charac-
teristic (ROC) curve. Area under the receiver operating
characteristic curve for histologic inﬂammation versus no
inﬂammation was estimated: 1.0 is characteristic of an ideal
test, whereas 0.5 indicates a test of no diagnostic value.
Statistical data analysis was performed by using the
Statistical Package for Social Science version 13.0 for
Windows.
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RESULTS
A total of 382 outpatients were interviewed. Of these,
36 (9.4%) were deemed ineligible based on 1 or more
exclusion criteria. The remaining 346 (90.6%) patients were
included in the study.
In detail, endoscopy was normal in 242 patients
(69.9%); colorectal polyps were found in 10 (2.9%), IBD in
82 (23.7%), uncomplicated diverticula in 11 (3.2%), and
ischemic colitis in 1 patient (0.3%). Median levels of FC for
the above-speciﬁed 5 diagnostic groups are shown in Fi-
gure 1. When compared with patients with normal endos-
copy, median FC levels were signiﬁcantly higher in all the
other groups (P<0.0001, Spearman correlation rank test).
Histologic ﬁndings included 142 patients (41.0%) with
inﬂammation and 204 (59.0%) without it. Median levels of
FC the above 2 groups are shown in Figure 2. Median FC
levels were signiﬁcantly higher in patients with in-
ﬂammatory conditions (P<0.0001, Spearman correlation
rank test) compared with those normal histologic ﬁndings.
The main ﬁnal diagnosis among the patients with
histologic inﬂammation was IBD in 82 (56 Crohn’s disease
and 26 ulcerative colitis). Miscellaneous conditions were
found in 17 (microscopic colitis=6; diverticular di-
sease=4; polyps=6; ischemic colitis=1). In 22 patients,
the pathology ﬁndings reported a diagnosis of nonspeciﬁc
colitis. The remaining 21 patients had a clinical diagnosis of
IBS based on the history (Roma criteria) and on the ab-
sence of any red ﬂags (screening blood and stool structural
colonic evaluation), despite their mild lymphocytic in-
ﬁltration. The ﬁnal diagnosis for the group of patients
without histologic inﬂammation was IBS for 197 subjects
and diverticular disease in 7; in addition we found 4 colonic
polyps on colonoscopy.
Demographic and clinical data are provided according
to the presence of histologic inﬂammation (Table 1). Sex
distribution (P= 0.014) diﬀered among the groups, with a
predominance of females without inﬂammation. Median
ESR (P<0.0001) and FC (P<0.001) values were si-
gniﬁcantly higher in patients with inﬂammation.
Associations between demographic, laboratory, and
histologic data according to FC levels are summarized
in Table 2. Age distribution was similar among study
participants, though sex distributions diﬀered (P= 0.02),
with females predominance.
Based on a multivariate linear logistic regression
model, the presence of histologic inﬂammation (P<0.0001;
OR 6.54; 95% CI, 3.30-12.96) and higher ESR values
(P<0.0001; OR 1.09; 95% CI, 1.06-1.23) were signiﬁcantly
and independently associated with FC levels.
To appraise the best FC value able to recognize his-
tologic inﬂammation, we constructed an ROC curve and
calculated that the optimized cut-oﬀ point for equally im-
portant sensitivity and speciﬁcity was >150mcg/g of stool
(Fig. 3). At this cutoﬀ, FC had 75.4% sensitivity, 88.3%
speciﬁcity, 81.7% positive predictive values, and 83.7%
negative predictive values in predicting inﬂammation on
histology. Based on ROC curve, FC was a sensitive bio-
marker for histologic inﬂammation at all speciﬁcities
(AUC=0.9, 95% CI, 0.82-0.89).
DISCUSSION
IBS is probably the most frequent cause of chronic
diarrhea in adults, aﬀecting 10% to 20% of the general
population.12 Although simple clinical criteria based on
medical history and physical examination are suggested for
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FIGURE 1. Median fecal calprotectin levels according to endo-
scopic diagnosis. Box and whisker plots showing fecal calpro-
tectin levels (mcg/g of stool) in patients stratified according the
endoscopic diagnoses.
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FIGURE 2. Fecal calprotectin distribution according to histologic
inflammation. Box and whisker plots showing fecal calprotectin
levels (mcg/g of stool) in patients stratified in those with and
without histologic inflammation. The horizontal line represents
the reference value of 150mcg/g of stool. P by the Spearman
correlation rank coefficient. IBD indicates inflammatory bowel
disease.
TABLE 1. Demographic, ,Laboratory and Histologic Features of
346 Consecutive Patients With Chronic Diarrhea According to
Histology
Histologic Inﬂammation
Variable No (n=204) Yes (n=142) P
Sex
Male 74 (36.3) 71(50.0) 0.014
Female 130 (63.7) 71 (50.0)
Age (y) 38.0 (18-87) 41 (17-80) 0.07
ESR 6 (2-52) 28 (2-115) <0.0001
CRP (n=109) 0.08 (0.01-15.3) 0.47 (0.01-7.3) 0.08
FC 45 (5-225) 300 (10-600) <0.001
Data are given as median (range) or as number of cases (%).
CRP indicates C-reactive protein; ESR, erythrocyte sedimentation rate;
FC, fecal calprotectin.
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a diagnosis of IBS,13 a deﬁnitive diagnosis is still reached by
excluding other diseases, thus following a more or less ag-
gressive investigation plan.14
To limit the numerous and invasive investigations,
several noninvasive blood tests have been suggested, but
their sensitivity and speciﬁcity are quite low, and they do
not directly reﬂect the level of colonic inﬂammation.15,16
Several studies have proposed leukocyte-derived protein
assay as a means of identifying inﬂammatory versus func-
tional causes of chronic diarrhea.9,17–19
We tested FC as a biomarker of intestinal inﬂam-
mation because of its diagnostic capability is considered
superior to other acute-phase reactant proteins released
during inﬂammation in the gastrointestinal tract.20 Cal-
protectin has characteristics that might facilitate its use
including existence in a preformed state within white blood
cells, resistance to proteolytic enzymes, stability in stool,
and ease in measuring.10,21 Moreover, FC has been pro-
posed as a comprehensive marker of organic gastro-
intestinal disorders.22
Our data show that among patients referred for co-
lonoscopy, FC levels are suﬃciently accurate in identifying
those with signiﬁcant colonic organic disease. In contrast to
these ﬁndings, Meucci et al23 reported that elevated cal-
protectin levels were found in as many as 36% of patients
with normal colonoscopy.
In our study, FC was found to be a biomarker strongly
associated with histologic inﬂammation among colono-
scopy referral patients with chronic, nonbloody diarrhea of
unknown origin. This ﬁnding is biologically intuitive, in as
much as leukocytes concentrate within inﬂamed intestinal
mucosa and, unlike erythrocytes, do not require vascular
disruption for their luminal release.
To appropriately interpret the fecal assay results, certain
features of our patient population are worthy of consid-
eration. All participants had been referred for colonoscopy,
which might have led to the selection of an analytic cohort
with an unusually high prevalence of organic pathology.
However, the proportion of our subjects with inﬂammatory
conditions was not markedly diﬀerent from that observed in
another chronic diarrhea series,2 which argues against this
possibility. We also used gastrointestinal bleeding as an ex-
clusion criterion, so our ﬁndings do not pertain to patients
with chronic bloody diarrhea. Nonetheless, this symptom
would usually prompt endoscopic evaluation without a need
for preliminary stool testing, and does not diminish the po-
tential value of FC screening.
In our study, ROC curve analysis of FC levels showed
that a cut-oﬀ point of 150mcg/g of stool had 75.4% sen-
sitivity for histologic inﬂammation, with 83.7% NPV.
These results indicate that the FC assay may be a useful
screening tool in the evaluation of patients with chronic,
nonbloody diarrhea. The present data are in agreement
with previous studies that have shown that FC is a highly
sensitive test for mucosal inﬂammation2,24 and a useful
marker in discriminating between organic and nonorganic
disease.19 The reported sensitivity oscillates between 63%
and 95%, whereas speciﬁcity has been reported to be
between 79% and 93%.9,17,18,24
Using the cut-oﬀ point of 150mcg/g of stool, about
12% of the IBS patients had calprotectin levels ranging
from 173 to 182mcg/g of stool. In such cases, the possibility
of day-to-day variations should be kept in mind, as shown
by a study in which a marked variability of calprotectin was
found on repeated assessments in 64% of patients without
neoplasm or inﬂammation.25 The proposed infective hypo-
thesis could provide a possible explanation for the high
fecal calprotectin values in IBS patients.26 If true, it is likely
that IBS patients will have leukocytes inﬁltrate in their
intestinal wall. Another possibility is the presence of
undiagnosed microscopic colitis. The diagnostic value of
FC may also be limited in patients with collagenous colitis,
as up to 40% of the patients with active collagenous colitis
are reported to have a normal calprotectin excretion.27
Our data suggest that resource utilization, especially of
expensive and invasive procedures like colonoscopy might be
more rationally and cost eﬀectively directed, based on the
determination of FC levels. The FC assay may have addi-
tional uses beyond its proposed function; by using a combi-
nation of clinical factors, such as age, symptoms, and
noninvasive fecal markers, a signiﬁcant proportion of pa-
tients with IBS could avoid further invasive investigations,
reserving endoscopy only for those with elevated FC con-
centrations. This strategy is likely to have beneﬁcial resource
and cost implications for endoscopy services, as up to 40% of
new gastroenterology referrals are for patients with suspected
IBS.28 Waiting lists for nonurgent colonoscopy may be many
TABLE 2. Univariate and Multivariate Analysis of Demographic,
Laboratory, and Histologic Features Associated With Elevated FC
Levels in 346 Consecutive Patients With Chronic Diarrhea
Univariate
Analysis
Multivariate
Analysis
SE P OR (95% CI) P
Sex 0.61 0.02 1.71 (0.91-3.20) 0.09
Age (y) 0.018 0.26 — —
Histologic
inﬂammation
0.69 0.004 6.54 (3.30-12.96) <0.0001
ESR 0.02 0.01 1.09 (1.06-1.23) <0.0001
CRP 0.27 0.23 — —
CI indicates conﬁdence interval; CRP, C-reactive protein; ESR, eryth-
rocyte sedimentation rate; FC, fecal calprotectin; OR, odds ratio.
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FIGURE 3. Receiver operating characteristic curve for fecal cal-
protectin in detecting histologic inflammation.
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months in some centers, and an elevated FC result may in-
dicate that a patient requires urgent endoscopic assessment.
Conversely, an FC concentration of <150mcg/g of stool is
unlikely to be associated with intestinal inﬂammation, and
investigations can be tailored appropriately.
In conclusion, our results suggest that FC reﬂects the
inﬂammatory status of the intestinal mucosa. The simplicity
of the methods, as well as the sensitivity, propose that FC
may be an ideal routine screening tool for the diagnosis of
organic intestinal disease. Our data suggest that resource
utilization, especially of expensive and invasive procedures
like colonoscopy, might be more rationally and cost eﬀec-
tively directed based on the determination of FC levels.
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